CoChat

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus

Bays, Harold · 2009 · Current Medical Research and Opinion

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Elevated glucose blood levels are the key criteria for diagnosing diabetes mellitus (DM). Hyperglycaemia contributes to the pathophysiology associated with DM, including microvascular and possibly macrovascular disease. In spite of a wide range of pharmacological options available to reduce hyperglycaemia in DM, epidemiological studies suggest that glucose levels remain high in a substantial proportion of patients. This supports the need for additional strategies for the treatment of hyperglycaemia. SCOPE: This review focuses on the role of the kidney in glucose reabsorption and explores inhibition of renal glucose reabsorption as a novel approach to treat type 2 DM. A literature search to August 2008 using PubMed was used to compile data for review. Abstracts and presentations from the American Diabetes Association and the European Association for the Study of Diabetes, the American Society of Nephrology, and the International Society of Nephrology Annual Meetings were also searched for relevant studies. FINDINGS: Glucose filtered by the kidney is normally reabsorbed into the proximal renal tubule. Data from animal models suggest that approximately 90% of this reabsorption occurs through the sodium-coupled glucose cotransporter (SGLT) 2, which is a protein expressed almost exclusively in the proximal tubule of the kidney. Inhibition of SGLT2, and thus inhibition of renal glucose reabsorption, has the potential to reduce hyperglycaemia in patients with DM. Patients with familial renal glucosuria, a genetic disorder of SGLT2, do not appear to have adverse clinical consequences related to impaired renal reabsorption of glucose, which suggests that SGLT2 might be both an effective and safe treatment target for hyperglycaemia. In animal models of DM, pharmaceutical inhibition of SGLT2 reduces hyperglycaemia, and may improve insulin resistance. CONCLUSION: Reduction of renal glucose reabsorption is a novel approach to DM treatment that potentially provides improvements in glucose lowering. Various SGLT2 inhibitors are currently in development in human trials.

Overview

Integrity signals

Registry

Crossref · 10.1185/03007990802710422

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Research works printed but not linked: 9

  1. Kosachunhanun N, 2006, J Med Assoc Thai, 89, S66
  2. Reaven GM, 2005, Panminerva Med, 47, 201
  3. Tsujihara K, 1996, I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo), 44, 1174
  4. Isaji M, 2007, Curr Opin Investig Drugs, 8, 285
  5. Glombik H, 2004, Chem Abstr, 140
  6. Washburn W, 2003, Chem Abstr, 138
  7. Komoroski B, 2009, Clin Pharmacol Ther
  8. Leslie B, 2008, American Society of Nephrology Renal Week
  9. Goudswaard AN, 2004, Cochrane Database Syst Rev

Cited by

See all 86

Metadata

Authors
Bays, H.
Affiliations
Louisville Metabolic and Atherosclerosis Research Center (US)
Corresponding author
Bays, Harold
Venue
Current Medical Research and Opinion
Published
2009-01-28
Volume
25
Issue
3
Pages
671-681
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2154020052
Cited by
83
References
56
Citations by year
2026: 3 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 9 · 2016: 5 · 2015: 9 · 2014: 7 · 2013: 5 · 2012: 5
FWCI
0.66
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
SGLT2 inhibitors, type 2 diabetes, renal glucose reabsorption, hyperglycemia, proximal tubule, insulin resistance, glucose-lowering therapy
MeSH terms
Diabetes Mellitus, Glucose, Humans, Kidney, Monosaccharide Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.